GlassScriptPhysician profile
Sneha Patel Cipriano
NPI 1780895292
$1,200.66
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $66.13 · 2021: $285 · 2022: $177 · 2023: $203 · 2024: $46.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $419.67 | 2019-2022 | |
| Merz North America, INC. | $242.54 | 2020-2023 | Xeomin |
| Angiodynamics, INC. | $119.42 | 2019-2023 | Venacure 1470 Pro |
| Bard Peripheral Vascular, INC. | $70.33 | 2021-2023 | |
| Lilly USA, LLC | $53.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.35 | 2019 | |
| Amgen INC. | $37.05 | 2019 | |
| Galderma Laboratories, L.P. | $35.92 | 2022 | |
| Merck Sharp & Dohme LLC | $35.65 | 2019 | |
| Boston Scientific Corporation | $34.00 | 2023-2024 | Varithena Administration Pack |
| Medtronic, INC. | $31.08 | 2024 | Venaseal |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Novo Nordisk INC | $18.34 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2020 | |
| Kaleo, INC. | $13.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Cipriano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.